488 related articles for article (PubMed ID: 24249759)
21. [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].
Camafort-Babkowski M
Med Clin (Barc); 2013 Aug; 141(4):167-74. PubMed ID: 23332622
[TBL] [Abstract][Full Text] [Related]
22. Glucagon-like peptide-1 agonists.
Padwal R
BMJ; 2012 Jan; 344():d7282. PubMed ID: 22236410
[No Abstract] [Full Text] [Related]
23. Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials.
Su B; Sheng H; Zhang M; Bu L; Yang P; Li L; Li F; Sheng C; Han Y; Qu S; Wang J
Endocrine; 2015 Feb; 48(1):107-15. PubMed ID: 25074632
[TBL] [Abstract][Full Text] [Related]
24. GLP-1 receptor agonists: a clinical perspective on cardiovascular effects.
Mundil D; Cameron-Vendrig A; Husain M
Diab Vasc Dis Res; 2012 Apr; 9(2):95-108. PubMed ID: 22496442
[TBL] [Abstract][Full Text] [Related]
25. Liraglutide in the treatment of obesity.
Ng SY; Wilding JP
Expert Opin Biol Ther; 2014 Aug; 14(8):1215-24. PubMed ID: 24905058
[TBL] [Abstract][Full Text] [Related]
26. Adjunctive Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Type 1 Diabetes Mellitus.
Harris KB; Boland CL
Pharmacotherapy; 2016 Sep; 36(9):1011-20. PubMed ID: 27485823
[TBL] [Abstract][Full Text] [Related]
27. Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials.
Monami M; Dicembrini I; Nardini C; Fiordelli I; Mannucci E
Diabetes Res Clin Pract; 2014 Feb; 103(2):269-75. PubMed ID: 24485345
[TBL] [Abstract][Full Text] [Related]
28. GLP-1 receptor agonists: effects on cardiovascular risk reduction.
Lorber D
Cardiovasc Ther; 2013 Aug; 31(4):238-49. PubMed ID: 23865382
[TBL] [Abstract][Full Text] [Related]
29. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials.
Monami M; Cremasco F; Lamanna C; Colombi C; Desideri CM; Iacomelli I; Marchionni N; Mannucci E
Exp Diabetes Res; 2011; 2011():215764. PubMed ID: 21584276
[TBL] [Abstract][Full Text] [Related]
30. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
[TBL] [Abstract][Full Text] [Related]
31. Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.
Monami M; Dicembrini I; Marchionni N; Rotella CM; Mannucci E
Exp Diabetes Res; 2012; 2012():672658. PubMed ID: 22675341
[TBL] [Abstract][Full Text] [Related]
32. Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake.
McKay NJ; Kanoski SE; Hayes MR; Daniels D
Am J Physiol Regul Integr Comp Physiol; 2011 Dec; 301(6):R1755-64. PubMed ID: 21975647
[TBL] [Abstract][Full Text] [Related]
33. High-fat diet changes the temporal profile of GLP-1 receptor-mediated hypophagia in rats.
Mul JD; Begg DP; Barrera JG; Li B; Matter EK; D'Alessio DA; Woods SC; Seeley RJ; Sandoval DA
Am J Physiol Regul Integr Comp Physiol; 2013 Jul; 305(1):R68-77. PubMed ID: 23616105
[TBL] [Abstract][Full Text] [Related]
34. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
35. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.
Monami M; Marchionni N; Mannucci E
Eur J Endocrinol; 2009 Jun; 160(6):909-17. PubMed ID: 19318378
[TBL] [Abstract][Full Text] [Related]
36. GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women.
Iepsen EW; Lundgren JR; Hartmann B; Pedersen O; Hansen T; Jørgensen NR; Jensen JE; Holst JJ; Madsbad S; Torekov SS
J Clin Endocrinol Metab; 2015 Aug; 100(8):2909-17. PubMed ID: 26043228
[TBL] [Abstract][Full Text] [Related]
37. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4.
Kanoski SE; Fortin SM; Arnold M; Grill HJ; Hayes MR
Endocrinology; 2011 Aug; 152(8):3103-12. PubMed ID: 21693680
[TBL] [Abstract][Full Text] [Related]
38. A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer.
Chiu WY; Shih SR; Tseng CH
Exp Diabetes Res; 2012; 2012():924168. PubMed ID: 22693487
[TBL] [Abstract][Full Text] [Related]
39. A multiplicity of targets: evaluating composite endpoint studies of the GLP-1 receptor agonists in type 2 diabetes.
Ross SA
Curr Med Res Opin; 2015 Jan; 31(1):125-35. PubMed ID: 25299351
[TBL] [Abstract][Full Text] [Related]
40. An update in incretin-based therapy: a focus on glucagon-like peptide-1 receptor agonists.
Edwards KL; Stapleton M; Weis J; Irons BK
Diabetes Technol Ther; 2012 Oct; 14(10):951-67. PubMed ID: 22845681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]